Clinical Pharmacy and Pharmacoepidemiology Research Group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium.
Institute of Health and Society (IRSS), UCLouvain, Brussels, Belgium.
BMJ Open. 2024 Oct 22;14(10):e085435. doi: 10.1136/bmjopen-2024-085435.
Despite several calls to deprescribe benzodiazepine receptor agonists (BZRA) in older adults, their use among nursing home residents (NHRs) remains high. Therefore, we developed an intervention targeting general practitioners' and healthcare professionals' behaviours regarding BZRA deprescribing in nursing homes (NHs): The END-IT NH (bENzodiazepines Deprescribing InTerventions Nursing homes) 6-component intervention. Before moving on to a large-scale effectiveness and cost-effectiveness evaluation, this feasibility study aims at: (1) assessing the feasibility of the intervention implementation in NHs, (2) assessing the feasibility of conducting a larger-scale evaluation, in terms of recruitment and data collection and (3) conducting an exploratory cost-effectiveness evaluation.
We will conduct a cluster-randomised controlled trial in a sample of 6 NHs, with 10-15 NHRs included per NHs. Four NHs will be randomised into the intervention group, and two NHs will deliver usual care (control group). Data collection will occur at baseline, 3, and 6 months (study end). We will collect information to explore implementation fidelity, mechanisms of impact and contextual factors at patient-level, NH-level and healthcare professional-level, using both quantitative and qualitative measures. The feasibility of the study conduction will be assessed by measuring recruitment and attrition rates and completeness of data collection. An exploratory cost-effectiveness evaluation will be conducted based on quality of life and healthcare use and cost data.
This study protocol received approval from the ethical committee of CHU UCL Namur on the 20 June 2023. All data are confidential and will be anonymised prior to analysis. De-identified data will be shared on a data depository with a 2-year embargo. The results of the study will be disseminated through a scientific paper and will be communicated to local stakeholders and policymakers through a local symposium.
NCT05929443.
尽管有几项呼吁减少老年人群中苯二氮䓬类受体激动剂(BZRA)的使用,但养老院居民(NHR)中仍大量使用。因此,我们针对全科医生和医疗保健专业人员在养老院中减少 BZRA 的行为,开发了一项干预措施:终止干预养老院(NH)中的 BZRA(bENzodiazepines Deprescribing InTerventions Nursing homes)6 组件干预。在进行大规模的有效性和成本效益评估之前,这项可行性研究旨在:(1)评估干预措施在 NH 中的实施可行性,(2)评估在招募和数据收集方面进行更大规模评估的可行性,以及(3)进行探索性成本效益评估。
我们将在一个由 6 个 NH 组成的样本中进行一项集群随机对照试验,每个 NH 中包含 10-15 名 NHR。将 4 个 NH 随机分配到干预组,2 个 NH 提供常规护理(对照组)。数据收集将在基线、3 个月和 6 个月(研究结束)进行。我们将收集信息,以探索患者层面、NH 层面和医疗保健专业人员层面的实施保真度、影响机制和背景因素,同时使用定量和定性措施。通过测量招募和流失率以及数据收集的完整性,评估研究的可行性。根据生活质量和医疗保健使用和成本数据,进行探索性成本效益评估。
本研究方案于 2023 年 6 月 20 日获得 CHU UCL Namur 伦理委员会的批准。所有数据均保密,并在分析前进行匿名处理。将对识别数据进行匿名化,在有 2 年保留期的数据存储库中共享。研究结果将通过科学论文进行传播,并通过当地研讨会向当地利益相关者和政策制定者传达。
NCT05929443。